Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10164157 | 1.00 | CA1 (0.33) | CA1CA2GABRR1DPP4EPHX1 | |
| SCHEMBL8963 | 1.00 | CA1 (0.33) | CA1CA2GABRR1DPP4EPHX1 | |
| SCHEMBL14321927 | 0.82 | PIK3CD (0.34) | CA1CA2GABRR1 | |
| SCHEMBL25098364 | 0.80 | CA1 (0.31) | CA1CA2GABRR1 | |
| SCHEMBL20154129 | 0.80 | ALDH1A1 (0.34) | CA1CA2GABRR1 | |
| SCHEMBL15672770 | 0.78 | CA1 (0.34) | CA1CA2EPHX1 | |
| SCHEMBL8621952 | 0.78 | CA1 (0.30) | CA1CA2 | |
| SCHEMBL11564015 | 0.78 | CA1 (0.31) | CA1 | |
| SCHEMBL1244953 | 0.77 | EPHX1 (0.34) | GABRR1EPHX1 | |
| SCHEMBL13180020 | 0.77 | EPHX1 (0.34) | GABRR1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859538-B2 | Uses of substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20110034443-A1 | USES OF SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034443-A1 | USES OF SUBSTITUTED IMIDAZOHETEROCYCLES | CNR2, CNR1, TRPV1 | CA1 1241/4885CA2 343/4885GABRR1 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.